Sildenafil Does Not Influence Hepatic Venous Pressure Gradient in Patients with Cirrhosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 Nov 6

PMID 18985812

Citations 19

Authors

Jens-Otto Clemmesen

Annamaria Giraldi

Peter Ott

Kim Dalhoff

Bent-Adel Hansen

Fin-Stolze Larsen

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate if sildenafil increases splanchnic blood flow and changes the hepatic venous pressure gradient (HVPG) in patients with cirrhosis. Phosphodiesterase type-5 inhibitors are valuable in the treatment of erectile dysfunction and pulmonary hypertension in patients with end-stage liver disease. However, the effect of phosphodiesterase type-5 inhibitors on splanchnic blood flow and portal hypertension remains essentially unknown.

Methods: Ten patients with biopsy proven cirrhosis (five females/five males, mean age 54 +/- 8 years) and an HVPG above 12 mmHg were studied after informed consent. Measurement of splanchnic blood flow and the HVPG during liver vein catheterization were done before and 80 min after oral administration of 50 mg sildenafil. Blood flow was estimated by use of indocyanine green clearance technique and Fick's principle, with correction for non-steady state.

Results: The plasma concentration of sildenafil was 222 +/- 136 ng/mL 80 min after administration. Mean arterial blood pressure decreased from 77 +/- 7 mmHg to 66 +/- 12 mmHg, P = 0.003, while the splanchnic blood flow and oxygen consumption remained unchanged at 1.14 +/- 0.71 L/min and 2.3 +/- 0.6 mmol/min, respectively. Also the HVPG remained unchanged (18 +/- 2 mmHg vs 16 +/- 2 mmHg) with individual changes ranging from -8 mmHg to +2 mmHg. In seven patients, HVPG decreased and in three it increased.

Conclusion: In spite of arterial blood pressure decreases 80 min after administration of the phosphodiesterase type-5 inhibitor sildenafil, the present study could not demonstrate any clinical relevant influence on splanichnic blood flow, oxygen consumption or the HVPG.

Citing Articles

Chronic liver diseases and erectile dysfunction.

Zang G, Sun X, Sun Y, Zhao Y, Dong Y, Pang K Front Public Health. 2023; 10:1092353.

PMID: 36684968 PMC: 9853559. DOI: 10.3389/fpubh.2022.1092353.

Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.

Lee S, Saffo S World J Gastroenterol. 2023; 29(1):61-74.

PMID: 36683719 PMC: 9850948. DOI: 10.3748/wjg.v29.i1.61.

Sexual dysfunctions and their treatment in liver diseases.

Jagdish R World J Hepatol. 2022; 14(8):1530-1540.

PMID: 36157870 PMC: 9453461. DOI: 10.4254/wjh.v14.i8.1530.

Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study.

Kumar A, Saraswat V, Pande G, Kumar R J Clin Exp Hepatol. 2022; 12(4):1083-1090.

PMID: 35814506 PMC: 9257884. DOI: 10.1016/j.jceh.2022.01.009.

Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis.

Yoo H, Lee B, Jung E, Kim S, Kim Y, Yoo J Hepatol Int. 2021; 17(2):452-462.

PMID: 34799837 DOI: 10.1007/s12072-021-10270-y.

References

Garcia-Pagan J, Santos C, Barbera J, Luca A, Roca J, Rodriguez-Roisin R . Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology. 1996; 111(5):1300-6. DOI: 10.1053/gast.1996.v111.pm8898644. View

Thiesson H, Jensen B, Jespersen B, de Muckadell O, Bistrup C, Walter S . Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2004; 288(5):F1044-52. DOI: 10.1152/ajprenal.00142.2004. View

Deibert P, Schumacher Y, Ruecker G, Opitz O, Blum H, Rossle M . Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. Aliment Pharmacol Ther. 2006; 23(1):121-8. DOI: 10.1111/j.1365-2036.2006.02735.x. View

Cooper J, Muirhead D, Taylor J, Baker P . Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997; 701(1):87-95. DOI: 10.1016/s0378-4347(97)00339-3. View

Ott P, Keiding S, Bass L . Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis. Hepatology. 1993; 18(6):1504-15. View

Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338(20):1397-404. DOI: 10.1056/NEJM199805143382001. View

Lebrec D, Nouel O, Corbic M, Benhamou J . Propranolol--a medical treatment for portal hypertension?. Lancet. 1980; 2(8187):180-2. DOI: 10.1016/s0140-6736(80)90063-x. View

Bellis L, Berzigotti A, Abraldes J, Moitinho E, Garcia-Pagan J, Bosch J . Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology. 2003; 37(2):378-84. DOI: 10.1053/jhep.2003.50053. View

Jensen S, Gluud C . Sexual dysfunction in men with alcoholic liver cirrhosis. A comparative study. Liver. 1985; 5(2):94-100. DOI: 10.1111/j.1600-0676.1985.tb00221.x. View

10.

Corbin J, Francis S . Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999; 274(20):13729-32. DOI: 10.1074/jbc.274.20.13729. View

11.

Perko M, Nielsen H, Skak C, Clemmesen J, Schroeder T, Secher N . Mesenteric, coeliac and splanchnic blood flow in humans during exercise. J Physiol. 1998; 513 ( Pt 3):907-13. PMC: 2231328. DOI: 10.1111/j.1469-7793.1998.907ba.x. View

12.

Boolell M, Gepi-Attee S, Gingell J, Allen M . Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996; 78(2):257-61. DOI: 10.1046/j.1464-410x.1996.10220.x. View

13.

Sampson L, HINTON J, Garland C . Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries. Br J Pharmacol. 2001; 132(1):13-7. PMC: 1572563. DOI: 10.1038/sj.bjp.0703831. View

14.

Muirhead G, Wilner K, Colburn W, Rouviex B . The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002; 53 Suppl 1:21S-30S. PMC: 1874252. DOI: 10.1046/j.0306-5251.2001.00029.x. View

15.

Skak C, Keiding S . Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver. 1987; 7(3):155-62. DOI: 10.1111/j.1600-0676.1987.tb00336.x. View

16.

Colle I, De Vriese A, Van Vlierberghe H, Lameire N, Devos M . Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int. 2004; 24(1):63-8. DOI: 10.1111/j.1478-3231.2004.00892.x. View

17.

Cornely C, Schade R, Van Thiel D, Gavaler J . Chronic advanced liver disease and impotence: cause and effect?. Hepatology. 1984; 4(6):1227-30. DOI: 10.1002/hep.1840040622. View

18.

Tandon P, Inayat I, Tal M, Spector M, Shea M, Groszmann R . Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(6):546-9. PMC: 2879450. DOI: 10.1016/j.cgh.2010.01.017. View

19.

Ghali-Ghoul R, Tahseldar-Roumieh R, Sabra R . Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. Eur J Pharmacol. 2007; 572(1):49-56. DOI: 10.1016/j.ejphar.2007.05.068. View

20.

Groszmann R, Bosch J, Grace N, CONN H, Garcia-Tsao G, Navasa M . Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990; 99(5):1401-7. DOI: 10.1016/0016-5085(90)91168-6. View